Population pharmacokinetics of tacrolimus in kidney transplant patients

International Journal of Clinical Pharmacology and Therapeutics

Volumn 48, Issue 6, 2010, Pages 375-382

  Velickovic Radovanovic, R ^a,b   Catic Djordjevic, A ^a   Milovanovic, J R ^c   Djordjevic, V ^b   Paunovic, G ^b   Jankovic, S M ^c  

^a UNIVERSITY OF NI   (Serbia)

^b Clinical Centre of Ni   (Serbia)

^c UNIVERSITY OF KRAGUJEVAC   (Serbia)

Author keywords

NONMEM; Population pharmacokinetics; Renal transplantation; Tacrolimus; Therapeutic drug monitoring

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CORTICOSTEROID; COTRIMOXAZOLE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OMEPRAZOLE; PREDNISOLONE; PREDNISONE; TACROLIMUS;

ADULT; AGE DISTRIBUTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY WEIGHT; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG MEGADOSE; EVENING DOSAGE; FEMALE; GRAFT RECIPIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; POSTOPERATIVE PERIOD; SEX DIFFERENCE;

EID: 77952759759     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP48375     Document Type: Article

References (26)

1. Anglicheau D, Flamant M, Schlageter M, Martinez F, Cassinat B, Beaune P, Legendre C, Thervet E. Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Nephrol Dial Transplant. 2003; 18: 2409-2414. (Pubitemid 37336834)
2. Antignac M, Barrou B, Farinotti R, Lechat P, Urien S. Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients. Br J Clin Pharmacol. 2007; 64: 750-757. (Pubitemid 350222052)
3. Antignac M, Hulot JS, Boleslawski E, Hannoun L, Touitou Y, Farinotti R, Lechat P, Urien S. Population pharmacokinetics of tacrolimus in full liver transplant patients: modelling of the post-operative clearance. Eur J Clin Pharmacol. 2005; 61: 409-416. (Pubitemid 41569318)
4. Bartlomiejczyk I, Zochowska D, Sanko-Resmer J, Matuszewicz D, Paczek L. Therapeutic monitoring of tacrolimus concentrations in blood of renal and liver transplant recipients: comparison of microparticle enzyme immunoassay and enzyme multi; 38: 94-96.
5. Beal SL, Sheiner LB. NONMEM Users Guides. California: NONMEM Project Group, University of San Francisko; 1998.
6. Benkali K, Prémaud A, Picard N, Rérolle J, Toupance O, Hoizey G; Turcant A, Villemain F, Yannick L, Marquet P, Rousseau A. Tacrolimus Population Pharmacokinetic-Pharmacogenetic Analysis and Bayesian Estimation in Renal Transplant Recipients Clin Pharmacokinet. 2009; 48: 805-816.
7. Cattaneo D, Baldelli S, and Perico N. Pharmacogenetics of immunosuppressants: progress, pitfalls and promises. Am J Transplant. 2008; 8: 1374-1383. (Pubitemid 351989490)
8. Dai Y, Hebert MF, Isoherranen N, Davis CL, Marsh C, Shen DD, Thumel KE. Effect of CYP- 3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab Dispos. 2006; 34: 836-847.
9. Holt DW, Armstrong VW, Griesmacher A, Morris Rg, Napoli KL, Shaw LM. International Federation of. Clinical Chemistry/International Association of Therapeutic Drug Monitoring and Clinical Toxicology Working Group on immunosuppressive drugmonitoring. Ther Drug Monit. 2002; 24: 59-67.
10. Iwasaki K. Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. Drug Metab Pharmacokinet. 2007; 22: 328-335.
11. Jusko WJ. Analysis of tacrolimus (FK 506) in relation to therapeutic drug monitoring. Ther Drug Monit. 1995; 17: 596-601.
12. Kahan B, Keown P, Levy G, Johnston A. Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. Clin Ther. 2002; 24: 330-350. (Pubitemid 34275858)
13. Lam S, Partovi N, Ting LS, Ensom MH. Corticosteroid interactions with cyclosporine, tacrolimus, mycophenolate, and sirolimus: fact or fiction? Ann Pharmacother. 2008; 42: 1037-1047.
14. Lee JY, Hahn HJ, Son IJ, Suh KS, Yi NJ, Oh JM, Shin WG. Factors affecting the apparent clearance of tacrolimus in Korean adult liver transplant recipients. Pharmacotherapy. 2006; 26: 1069-1077.
15. Li D, Lu W, Zhu JY, Gao J, Lou YQ,, Zhang GL. Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patients. J Clin Pharm Ther. 2007; 32: 505-515. (Pubitemid 47404287)
16. Masuda S, Inui K. An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. Pharmacol Ther. 2006; 112: 184-198. (Pubitemid 44301492)
17. Press RR, Ploeger BA, Den Hartigh J, Van Der Straaten T, Van Pelt J; Danhof M; DE Fijter JW, Guchelaar H. Explaining Variability in Tacrolimus Pharmacokinetics to Optimize Early Exposure in Adult Kidney Transplant Recipients. Ther Drug Monit. 2009; 31: 187-197.
18. Quteineh L, Verstuyft C, Furlan V, Durrbach A, Letierce A, Ferlicot S, Taburet AM, Charpentier B, Becquemint L. Influence of CYP3A5 genetic polymorfism on tacrolimus daily dose requirements and acute rejection in renal graft recipients. Basic Clin Pharmacol Toxicol. 2008; 103: 546-552.
19. Satoh S, Kagay, H, Sait, M, Inou, T; Miura M, Inoue K, Numakura K, Tsuchiya N, Tada H, Suzuki T, Habuchi T. Lack of tacrolimus circadian pharmacokinetics and CYP3A5 pharmacogenetics in the early and maintenance stages in Japanese renal transplant recipients. Br J Clin Pharmacol. 2008; 66: 207-214.
20. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981; 9: 503-512.
21. Staatz CE, Willis C, Taylor PJ, Lynch SV, Tett SE. Toward better outcomes with tacrolimus therapy: Population pharmacokinetics and individualized dosage prediction in adult liver transplantation. Liver Transpl. 2003; 9: 130-137.
22. Staatz CE, Willis C, Taylor PJ, Tett SE. Population phramacokinetics of tacrolimus in adult kidney transplant recipients. Clin Pharmacol Ther. 2002; 72: 660-669.
23. Undre NA. Pharmacokinetics of tacrolimus based combination therapies. Nephrol Dial Transplant. 2003; 18: 12-15.
24. Xin-Min N, Rong G, Hong-Shan Z. Influence of CYP3A5 polymorphism on tacrolimus blood concentrations in renal transplant patients. J Cent South Univ Technol. 2005; 12: 310-313.
25. Zahir H, McLachan AJ, Nelson A, McCaughan G, Gleeson M, Akhlaghi F. Population pharmacoce in adult liver transplant recipients. Ther Drug Monit. 2005; 27: 422-430.
26. Zhao W, Elie V, Roussey G, Brochard K, Niaudet P, Leroy V, Loirat C, Cochat P, Cloarec S, André JL, Garaix F, Bensman A, Fakhoury M, Jacqz-Aigrain E. Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients. Clin Pharmacol Ther. 2009; 86: 609-618